Oral deferiprone for iron chelation in people with thalassaemia.

Fisher, Sheila A; Brunskill, Susan J; Doree, Carolyn; Chowdhury, Onima; Gooding, Sarah; Roberts, David J

Fisher, Sheila A; Brunskill, Susan J; Doree, Carolyn; Chowdhury, Onima; Gooding, Sarah; Roberts, David J.

Affiliation

Fisher SA; Systematic Review Initiative, NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Headington, Oxford, Oxon, UK, OX3 9BQ.

Cochrane Database Syst Rev ; (8): CD004839, 2013 Aug 21.

Article in En | MEDLINE | ID: mdl-23966105

Subject(s)

Chelation Therapy/adverse effects; Deferoxamine/therapeutic use; Iron Chelating Agents/therapeutic use; Iron Overload/drug therapy; Pyridones/therapeutic use; Thalassemia/therapy; Administration, Oral; Deferiprone; Deferoxamine/adverse effects; Humans; Iron Chelating Agents/adverse effects; Iron Overload/etiology; Pyridones/adverse effects; Randomized Controlled Trials as Topic; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyridones / Thalassemia / Chelation Therapy / Iron Chelating Agents / Iron Overload / Deferoxamine Type of study: Clinical_trials / Etiology_studies / Guideline / Systematic_reviews Language: En Journal: Cochrane Database Syst Rev Year: 2013 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google